explore -WSS

explore

author：focus 2025-09-02 03:50:53 - browse：15996

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Cigna, Humana reportedly in talks to merge

WSS

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Cue Health's Covid

Cigna, Humana reportedly in talks to merge

Cell therapy fails to slow type 1 diabetes, but safety is established

Disappointing trial forces Pfizer to pivot on obesity medicine plans

hotspot

explore

explore

Psychedelics group wrestles with new pharma identity

Exact Sciences stock tumbles despite strong cancer detection sales

Sports medicine is finally prioritizing gender equality

UnitedHealth’s Optum accused of antitrust violations in California

The high cost of giving birth even with insurance

Element Biosciences CEO lays out genome sequencing strategy

After affirmative action ruling, medical educators look to 'holistic review'

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Affirmative action in medical school literally saved lives

MassMutual is introducing free genetic testing for members

leisure time

Cholera vaccine supply gets boost as demand surges globally

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Orangutan used medicinal plant to treat wound, first time ever seen

Cigna, Humana reportedly in talks to merge

Organ aging and disease risk measured by new blood test

Cholera vaccine supply gets boost as demand surges globally

leisure time

explore

explore

hotspot